You may have seen them before: the highlights of our work in 2018. But now, we want to share these with you in a clear, fresh new way.
We are thrilled to present our strategy for the period 2019-2023. Based on current trends and shifts in global health, we have sharpened our strategy and the critical issues we work on. In the coming years we will continue to work closely with partner organisations, and stay committed to striving for structural change to improve global public health, advocating the right to health for all.
In 2018, the governments of Ghana, Germany and Norway requested the World Health Organization (WHO) to take the lead in an initiative to improve the coordination of international cooperation in the health sector. As a result, 12 multilateral organizations involved in the health sector are preparing a plan to accelerate, align, account and assess their efforts in the health sector for realizing the Sustainable Development Goal for health: SDG3. We applaud this initiative; here is our input for an online civil society consultation.
At the beginning of this month, members of the Dutch Parliaments’ committee on Health, Welfare and Sport had a debate on medicines policy in The Netherlands. Subsequent to this debate, multiple motions have been submitted on which a voting session will take place today in The Hague. Prior to today’s voting round, Wemos wrote a voting advisory piece addressing the members of the committee, holding them accountable for their needed commitment towards these important issues.
From May 20-28, the 72nd session of the World Health Assembly (WHA) will take place in Geneva, Switzerland. Each year, senior health officials from the World Health Organization’s (WHO) Member States gather there to discuss the WHO’s progress, new goals and global health agenda and challenges. Wemos will be present as well as a civil society organization and attend sessions on Financing for Health, the Global Action Plan for Healthy Lives and Well-being and Access to Medicines.
Research shows major Dutch public investments in drug development
Overpriced, a report published today jointly by The Centre for Research on Multinational Corporation (SOMO) and Wemos, examines the extent of Dutch public funding of drug development, through donations, loans and/or investments. This funding occurs both directly by financing development of new medicines, and indirectly through investments made into biotech companies, but channelled through universities, public research bodies, and national and regional investment funds. The report reveals, however, that because no conditions are set on these investments, the Government loses its chance to curb subsequent high drug prices.
Why are (some) medicines so expensive? How are medicines developed in the Netherlands, and how does this system contribute to unequal access to medicines? In our new infographic we explain how the system works and why we think the EU and Dutch government can do more to ensure equal access to medicines for society.
There is increasing pressure on access to affordable, innovative medicines for many European citizens. Change is urgently needed. This key message emerges from the joint manifesto by several members of the Medicines Network Netherlands (Medicijnen Netwerk Nederland), of which Wemos is a member. The publication of the manifesto anticipates the European Parliament elections to be held on 23 May 2019.
Health workers worldwide are overburdened, burned out, and even being attacked while doing their job. Last week, during the World Health Worker Week 2019, there was a lot of attention for health workers worldwide. But actually they deserve this attention every week of the year. In their blogs, Wemos’ global health advocate Amanda Banda and Dr. Fredrick Oluga explain why we need less talk – and more action.
The adoption of the Sustainable Development Goals (SDGs) in 2015 led to increased global attention for the funding gap for health in low- and lower middle-income countries. Our new factsheet explains how governments can improve their health sectors by increasing their fiscal space for health and investing in their health workers.